Neoadjuvant Dual HER2-Inhibition Superior for HER2-Positive Breast Cancer

Share this content:

(ChemotherapyAdvisor) – For patients with HER2-positive operable breast cancer, dual-HER2 inhibition using preoperative chemotherapy plus trastuzumab and lapatinib was superior to chemotherapy plus either agent alone, the Phase 2 CHER-LOB study investigators reported in the Journal of Clinical Oncology online April 9.

In this noncomparative trial, 121 patients with HER2–positive, stage 2 to 3A operable breast cancer were randomly assigned to one of three arms: arm A received a 4mg loading dose of trastuzumab followed by 2mg weekly (n=36); arm B received lapatinib 1,500mg orally daily (n=39); and arm C received trastuzumab and lapatinib 1,000mg orally daily (n=46). All arms received weekly paclitaxel (80mg/m2) for 12 weeks followed by fluorouracil, epirubicin, and cyclophosphamide for four courses every three weeks. The primary goal was to estimate percentage of pathologic complete response (pCR; no invasive tumor in breast and axillary nodes).

Rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% in arms A, B, and C, respectively. The pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C (exploratory P=0.019). Patients receiving lapatinib had more frequently occurring dermatologic and hepatic toxicities and diarrhea; the protocol was amended to reduce the lapatinib dose to 1,250mg/day in arm B and to 750mg/day in arm C. No episodes of congestive heart failure were observed.

“Chemotherapy plus trastuzumab and lapatinib induced a pCR rate of 46.7%, which represents a relative increase of 80% in the pCR rate achieved with the same chemotherapy plus either trastuzumab or lapatinib,” they wrote. Although the pCR end point is an early surrogate for outcome, not survival — “the data from this trial add further evidence supporting the superiority of a dual-HER2 inhibition for the treatment of patients with HER2-positive breast cancer.”



Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs